Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Altria Group, Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $125.4B | |
|---|---|---|
| Revenue (ttm) | 20.4B | |
| Net income (ttm) | 8B | |
| EPS (ttm) | $4.75 | |
| Shares out | 1.7B | |
| P/E (trailing) | 15.3x | |
| P/E (forward) | 11.9x | |
| Dividend | $4.44 (6.09%) | |
| Volume | 4,522,438 | |
| Beta | 0.46 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $26.01B | $25.10B | $24.48B | $24.02B | $23.28B | -2.7% |
| Gross profit | $13.99B | $14.25B | $14.28B | $14.37B | $14.54B | +1.0% |
| Operating income | $11.56B | $11.92B | $11.55B | $11.24B | $9.90B | -3.8% |
| Net income | $2.48B | $5.76B | $8.13B | $11.26B | $6.95B | +29.4% |
| EPS (diluted) | $1.34 | $3.19 | $4.57 | $6.54 | $4.12 | +32.4% |
| EBITDA | $5.26B | $8.74B | $12.32B | $15.07B | $10.83B | +19.8% |
| R&D | $145.0M | $162.0M | $220.0M | $208.0M | $195.0M | +7.7% |
| SG&A | $2.43B | $2.33B | $2.77B | $214.0M | $2.26B | -1.8% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal operating path: combustible volume secular decline is successfully mitigated by disciplined, continuous price realization. Marlboro maintains premium dominance while discount brands like Basic capture trade-down smokers. Smoke-free progress is modest, with on! growing absolute volume but losing pouch category share to dominant competitors, and NJOY remaining sidelined. Operating cash flow remains robust around $9.0B-$9.5B, enabling steady dividend payments ($4.44 per share) and modest share buybacks. However, with market price ($75.11) exceeding mid fair value ($61.61), investor returns are constrained.
In the Bull scenario, adult consumer discretionary income recovers, curtailing discount trade-down. Regulatory enforcement against illicit disposable vapes redirects nicotine volume back into Marlboro and authorized oral nicotine pouches. Helix's national rollout of on! PLUS across 120,000 stores scales rapidly, turning the smoke-free segment into an accretive profit driver. Altria's FCF generation comfortably supports annual dividend increases and >$1B in annual share repurchases, justifying valuation near the top of the fair value range ($84.57).
| Ke ↓ / g → | 1.0% | 1.3% | 1.5% | 1.8% | 2.0% |
|---|---|---|---|---|---|
| 6.5% | $66.7 | $68.5 | $70.4 | $72.7 | $75.2 |
| 7.0% | $62.6 | $64.0 | $65.6 | $67.3 | $69.3 |
| 7.5% | $59.2 | $60.4 | $61.6 | $63.0 | $64.5 |
| 8.0% | $56.2 | $57.2 | $58.3 | $59.4 | $60.6 |
| 8.5% | $53.7 | $54.5 | $55.4 | $56.3 | $57.3 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |